Celldex Therapeutics, Inc. (NASDAQ:CLDX) Updates On METRIC Enrollment


Celldex Therapeutics, Inc. (NASDAQ:CLDX) continues to predict that METRIC enrollment will be finalized by the close of the third quarter of 2017. It is a Phase IIb randomized pilot trial of glembatumumab vedotin in folks with metastatic triple negative breast cancer.

The highlights

Celldex posted that Phase II study of glembatumumab vedotin has been permitted for oral presentation at imminent ASCO event. The updated statistics from the Phase II trial will be showcased at the ASCO Annual Meeting planned next month.

Enrollment recently finalized in the glembatumumab varlilumab and vedotin trial, with data from this trial anticipated in this year. Registration are current in the glembatumumab vedotin and checkpoint inhibitor trial in folks who failed checkpoint therapy, a population with obstructive treatment alternatives.

Celldex posted that Phase I trial of varlilumab and Opdivo® has been permitted for presentation at ASCO. The revised data from this Phase 1 trial will be presented imminent month in a presentation at the ASCO Yearly Meeting. This Phase II portion of the trial comprises cohorts in different types of cancer, counting ovarian cancer, colorectal cancer, and few more. The company is in the process of registering patients for the respective trial.

Celldex intends to close enrollment across all cohorts in the planned Phase II portion of the study in the first quarter of next year and will work together with Bristol-Myers Squibb to reveal data from the trial at an upcoming medical meeting. Data from the Phase I trial of varlilumab for treatment of solid tumors was mentioned in the Journal of Clinical Oncology.

The company reported that enrollment for Phase 1 trial of CDX-0158 is ongoing. This dose escalation trial in folks with advanced refractory GIST and KIT-positive tumors is planned to know MTD, suggest a dose for next trial and confirm CDX-0158 safety profile.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.